COVID-19 Serology in Oncology Staff Study: Understanding SARS-CoV-2 in the Oncology Workforce

  1. D.M. Favara
  2. A. Cooke
  3. R. Doffinger
  4. K. McAdam
  5. P. Corrie
  6. N.L. Ainsworth

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.clon.2020.07.015
  2. ScreenIT

    SciScore for 10.1101/2020.06.22.20136838: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: Following consent, samples were collected during the first week of June 2020, specifically, blood for SARS-COV-2 antibody testing and a nasopharyngeal swab for SARS-CoV-2 PCR testing.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The manufacturer claims that it has no cross-reactivity with antibodies against other coronavirus types (HKU1, OC43, NL63, 229E) and that it has a sensitivity of 98.5% and a specificity of 97.94%.
    NL63
    suggested: (Virostat Cat# 3878, RRID:AB_2889993)
    Software and Algorithms
    SentencesResources
    Data was analysed using Prism 8 (Graphpad Software).
    Graphpad
    suggested: (GraphPad, RRID:SCR_000306)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.06.22.20136838v1 on medRxiv